DFIN appears expensive at 39x trailing P/E but trades at ~11x forward P/E, revealing undervaluation vs. peers. GAAP earnings ...

Biotech's Phase III OptiTROP-Lung06 trial showed sac-TMT plus pembrolizumab cut lung cancer progression/death risk by 51% in ...

DataBull sells DataFast-style revenue analytics for $29 once, and Minilytics offers it free and open source. What fast, ...

Anthropic OSS Scanner gives open-source maintainers free Claude Mythos vulnerability scans; 88% of audited high-severity findings were valid.

NovaBridge Biosciences announced updated results from the Phase 1b study of givastomig, a bispecific antibody targeting ...

Updated Phase 1b dataset provides nearly 18 months of median follow-up and shows the durability of clinical benefit observed ...

REA AI reverse engineering is attracting attention for a provocative claim: AI agents can inspect existing applications and ...

IBM closed at $253.56 on 23 October, up 9.2 percent on the week after a Q3 beat. Software 9 percent, consulting flat, targets ...

Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week ...

Hotel technology provider dailypoint has launched a free and anonymous AI Readiness Check for hotels. The initiative comes as ...

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% ...

Tekion faced questions at a court hearing about the evidence supporting its allegations that CDK Global holds market power, with a California federal judge noting that artificial intelligence could ...